Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dendritic cell survivin vaccine
- Development stage
- Phase 1
- Lead developer
- Moffitt Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
The dendritic cell survivin vaccine (specifically DC:AdmS) is an autologous cancer vaccine composed of a patient's own dendritic cells that have been genetically modified using a replication-deficient adenoviral vector to express the survivin protein. Survivin (BIRC5) is a member of the inhibitor of apoptosis protein (IAP) family that is highly expressed in various malignancies, including multiple myeloma and glioblastoma, while being nearly absent in normal adult tissues. By presenting survivin-derived peptides via MHC class I and II molecules, the vaccine is designed to prime and expand survivin-specific CD8+ and CD4+ T cells. In clinical settings, particularly for multiple myeloma, it is often administered in conjunction with autologous hematopoietic cell transplantation (HCT) to leverage the period of lymphopenia-induced homeostatic proliferation to enhance the anti-tumor immune response.
- Other names
- DC-survivin vaccinesurvivin-pulsed dendritic cell vaccinesurvivin vaccineAd-survivin-transduced dendritic cell vaccine
02
Targets
BIRC5 (Survivin)
Beyond the preview
Go deeper on dendritic cell survivin vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dendritic cell survivin vaccine.